Buy Stocks Easy | About Us
April 21, 2021
Buy Stocks Easy | Online Stocks

AVXL


Buy Anavex Life Sciences Corp. Stock (symbol: AVXL) Easy Online

Company Name: Anavex Life Sciences Corp.

Symbol: AVXL

Sector: Health Care

Industry: Biotechnology: Commercial Physical & Biological Resarch

IPO: 2006

AVXL Current Share Price

Today's AVXL ( Anavex Life Sciences Corp. ) opening price: $2.4100

Yesterday's AVXL ( Anavex Life Sciences Corp. ) closing price: $2.4100

Anavex Life Sciences Corp. Stock ( symbol: AVXL ) Price Chart since IPO (2006):

12 Months Anavex Life Sciences Corp. Stock ( symbol: AVXL ) Price Chart

Popular Questions about Anavex Life Sciences Corp. Public Stock ( AVXL )

A: Anavex Life Sciences Corp. stock symbol (also called stock or share ticker) is AVXL

A: Anavex Life Sciences Corp. IPO (Initial Public Offering) took place on 2006

A: Anavex Life Sciences Corp.'s stock (AVXL symbol) price at ther IPO (initial Public Offering) was $2.4100

Q: Is AVXL stock worth buying at the moment?

A: If you were looking for a long-term investment portfolio and had bought the 'Anavex Life Sciences Corp. stock (symbol: AVXL) at the beginning of 2019, at the opening share price of $1.8500, with a minimum of $200, by now your shares would be worth $21820 and your profit would be $21620 - SHOW ONLY IF PROFIT.

Buy Anavex Life Sciences Corp. Stock Easy Online

Anavex Life Sciences Corp. Stock Ticker Price Chart since IPO:





Anavex Life Sciences Corp. Stock Price Yesterday



 


Anavex Life Sciences Corp. Stock Price – Last Week




 


Anavex Life Sciences Corp. Stock Price – Last Month




 


Anavex Life Sciences Corp. Stock Value Chart – 12 Months




            

                

                    

                    
                

                
                
Rate this post

                
            

            
            

             

            

        

    



            



    

        

            

                
 Latest Stock News: 

            

        

        



                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/11/14/1947083/0/en/Anavex-Life-Sciences-Receives-Rare-Pediatric-Disease-Designation-from-FDA-for-ANAVEX-2-73-blarcamesine-for-the-Treatment-of-Rett-Syndrome.html
                            

                                
Anavex Life Sciences Receives Rare Pediatric Disease Designation from FDA for ANAVEX®2-73 (blarcamesine) for the Treatment of Rett Syndrome

                                
                                
NEW YORK, Nov.  14, 2019  (GLOBE NEWSWIRE) -- Anavex Life Sciences ...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/11/06/1941970/0/en/Anavex-Life-Sciences-Announces-Publication-of-Foundational-Data-for-ANAVEX-2-73-blarcamesine-in-Rett-Syndrome.html
                            

                                
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome

                                
                                
Published in Pharmacology Biochemistry and Behavior, Results Highli...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/09/1927217/0/en/Anavex-Life-Sciences-Announces-ATTENTION-AD-ANAVEX-2-73-Extension-Clinical-Study-in-Early-Alzheimer-s-Disease.html
                            

                                
Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease

                                
                                
The ATTENTION-AD extension study will offer the 450 patients enroll...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/02/1923935/0/en/Anavex-Life-Sciences-Issued-New-U-S-Patent-for-Composition-of-Matter-Covering-ANAVEX-2-73-for-the-Treatment-of-Alzheimer-s-Disease.html
                            

                                
Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73 for the Treatment of Alzheimer’s Disease

                                
                                
NEW YORK, Oct.  02, 2019  (GLOBE NEWSWIRE) -- Anavex Life Sciences ...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/27/1921667/0/en/Anavex-Life-Sciences-Presented-at-the-6th-Annual-European-Rett-Syndrome-Conference-Preliminary-Clinical-Efficacy-Data-from-the-U-S-Rett-Syndrome-Phase-2-ANAVEX-2-73-Study.html
                            

                                
Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from the U.S. Rett Syndrome Phase 2 ANAVEX®2-73 Study

                                
                                
NEW YORK, Sept.  27, 2019  (GLOBE NEWSWIRE) -- Anavex Life Sciences...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/26/1921142/0/en/Anavex-Life-Sciences-to-Present-at-the-2019-Cantor-Fitzgerald-Global-Healthcare-Conference.html
                            

                                
Anavex Life Sciences to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

                                
                                
NEW YORK, Sept.  26, 2019  (GLOBE NEWSWIRE) -- Anavex Life Sciences...


                            

                        
                    

                


                            

                    


                        
                            https://www.benzinga.com/analyst-ratings/analyst-color/19/09/14475189/biotech-stock-on-the-radar-anavex-a-neurology-focused-precision-medicine-company
                            

                                
Biotech Stock On The Radar: Anavex, A Neurology-Focused Precision Medicine Company

                                
                                
The European Rett Syndrome Conference gets underway Friday in Finla...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/11/14/1947083/0/en/Anavex-Life-Sciences-Receives-Rare-Pediatric-Disease-Designation-from-FDA-for-ANAVEX-2-73-blarcamesine-for-the-Treatment-of-Rett-Syndrome.html
                            

                                
Anavex Life Sciences Receives Rare Pediatric Disease Designation from FDA for ANAVEX®2-73 (blarcamesine) for the Treatment of Rett Syndrome

                                
                                
NEW YORK, Nov.  14, 2019  (GLOBE NEWSWIRE) -- Anavex Life Sciences ...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/11/06/1941970/0/en/Anavex-Life-Sciences-Announces-Publication-of-Foundational-Data-for-ANAVEX-2-73-blarcamesine-in-Rett-Syndrome.html
                            

                                
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome

                                
                                
Published in Pharmacology Biochemistry and Behavior, Results Highli...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/09/1927217/0/en/Anavex-Life-Sciences-Announces-ATTENTION-AD-ANAVEX-2-73-Extension-Clinical-Study-in-Early-Alzheimer-s-Disease.html
                            

                                
Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease

                                
                                
The ATTENTION-AD extension study will offer the 450 patients enroll...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/02/1923935/0/en/Anavex-Life-Sciences-Issued-New-U-S-Patent-for-Composition-of-Matter-Covering-ANAVEX-2-73-for-the-Treatment-of-Alzheimer-s-Disease.html
                            

                                
Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73 for the Treatment of Alzheimer’s Disease

                                
                                
NEW YORK, Oct.  02, 2019  (GLOBE NEWSWIRE) -- Anavex Life Sciences ...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/27/1921667/0/en/Anavex-Life-Sciences-Presented-at-the-6th-Annual-European-Rett-Syndrome-Conference-Preliminary-Clinical-Efficacy-Data-from-the-U-S-Rett-Syndrome-Phase-2-ANAVEX-2-73-Study.html
                            

                                
Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from the U.S. Rett Syndrome Phase 2 ANAVEX®2-73 Study

                                
                                
NEW YORK, Sept.  27, 2019  (GLOBE NEWSWIRE) -- Anavex Life Sciences...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/26/1921142/0/en/Anavex-Life-Sciences-to-Present-at-the-2019-Cantor-Fitzgerald-Global-Healthcare-Conference.html
                            

                                
Anavex Life Sciences to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

                                
                                
NEW YORK, Sept.  26, 2019  (GLOBE NEWSWIRE) -- Anavex Life Sciences...


                            

                        
                    

                


                            

                    


                        
                            https://www.benzinga.com/analyst-ratings/analyst-color/19/09/14475189/biotech-stock-on-the-radar-anavex-a-neurology-focused-precision-medicine-company
                            

                                
Biotech Stock On The Radar: Anavex, A Neurology-Focused Precision Medicine Company

                                
                                
The European Rett Syndrome Conference gets underway Friday in Finla...


                            

                        
                    

                


            
        

    




    
    





	
	  

	  All right reserved Buy Stocks Easy , 2019.